Answers are grounded in this paper and cite their sources.
Probiotic strains intended for use in the oral cavity and upper respiratory tract are exposed to substantially higher oxygen levels than strains targeting the intestinal environment. We hypothesised that continuous oxygen exposure of an established probiotic strain used under conditions of high oxidative pressure, namely Limosilactobacillus reuteri ATCC PTA 5289 (Lr5289), would enable the natural selection of a variant better adapted to such an environment. Using this approach, the novel strain L. reuteri BG-R33® (DSM 33633) was obtained and demonstrated improved tolerance to an oxygen-rich environment. Interestingly, the strain also exhibited increased tolerance to hydrogen peroxide, a frequent challenge in the oral environment. In addition, compared to its progenitor, the novel strain showed a slightly improved capacity to inhibit the oral pathogen Streptococcus mutans and enterotoxigenic Escherichia coli, mainly through production of the antimicrobial metabolite reuterin. Tolerance to gastrointestinal stressors was also evaluated, and BG-R33® displayed increased bile tolerance compared with Lr5289, whereas tolerance to low pH (2.0) and adhesion to mucus and saliva did not differ between the strains. Both the genotype and phenotype of the novel strain were shown to be stable. Finally, BG-R33® was characterised in direct comparison with Lr5289 and exhibited a similar genomic and phenotypic safety profile, with no concerns identified. These subtle but distinct differences between the strains provide a rationale for further investigation of L. reuteri BG-R33® for applications targeting disorders of the oral cavity and upper respiratory tract.
No takes yet. Share an insight, caveat, or question.
Sendelius et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: